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Abstract
The filoviruses, Ebola (EBOV) and Marburg (MARV), cause a lethal hemorrhagic fever. Human
isolates of MARV are not lethal to immmunocompetent adult mice and, to date, there are no
reports of a mouse-adapted MARV model. Previously, a uniformly lethal EBOV-Zaire mouse-
adapted virus was developed by performing 9 sequential passages in progressively older mice
(suckling to adult). Evaluation of this model identified many similarities between infection in mice
and nonhuman primates, including viral tropism for antigen-presenting cells, high viral titers in the
spleen and liver, and an equivalent mean time to death. Existence of the EBOV mouse model has
increased our understanding of host responses to filovirus infections and likely has accelerated the
development of countermeasures, as it is one of the only hemorrhagic fever viruses that has
multiple candidate vaccines and therapeutics. Here, we demonstrate that serially passaging liver
homogenates from MARV-infected severe combined immunodeficient (scid) mice was highly
successful in reducing the time to death in scid mice from 50–70 days to 7–10 days after MARV-
Ci67, -Musoke, or -Ravn challenge. We performed serial sampling studies to characterize the
pathology of these scid mouse-adapted MARV strains. These scid mouse-adapted MARV models
appear to have many similar properties as the MARV models previously developed in guinea pigs
and nonhuman primates. Also, as shown here, the scid-adapted MARV mouse models can be used
to evaluate the efficacy of candidate antiviral therapeutic molecules, such as phosphorodiamidate
morpholino oligomers or antibodies.
Background
The family Filoviridae consists of two genera called ebola-
virus (EBOV) and marburgvirus (MARV) that are consid-
ered significant public health threats due to their very high
morbidity and mortality rates (up to 90% case fatality
rate), human-to-human transmissibility, and environ-
mental stability. Due to these characteristics, and the fact
that the filoviruses have a low infectious dose [<1 plaque-
forming units (pfu)] and can be easily produced to >108
pfu/ml in vitro or in vivo [1-4], the filoviruses are classified
as biosafety level (BSL)-4 agents and Category A biothreat
agents by the Centers for Disease Control and Prevention
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[5,6]. Initial symptoms of filovirus infection include non-
specific clinical signs such as high fever, headache, myal-
gia, vomiting and diarrhea, followed by leukopenia,
thrombocytopenia, lymphadenopathy, pharyngitis,
edema, hepatitis, maculopapular rash, hemorrhage, and
prostration with death generally occurring within 5–10
days of infection [1,7].
The first known filovirus outbreaks occurred in simultane-
ously in both Germany and Yugoslavia in 1967 when lab-
oratory workers became infected from blood and tissues
of MARV-infected African green monkeys imported from
Uganda [8,9]. Subsequent MARV cases or outbreaks have
occurred in South Africa, Zimbabwe, Kenya, Democratic
Republic of Congo, and Angola with case fatality rates
ranging from 20% in Germany in 1967 [8,9] to >90% in
Angola during 2004–5 [10]. It is generally considered that
transmission of the filoviruses requires direct contact with
blood, body fluids, or tissues from an infected individual
[11,12], although droplet and aerosol transmissions may
also occur [13].
Human-derived Marburg viruses (isolates Musoke, Ravn,
and Ci67) are not lethal to immmunocompetent adult
mice. Previously, an Ebola Zaire mouse-adapted virus was
developed by performing 9 sequential passages of Ebola
Zaire '76 virus in suckling mice followed by two sequen-
tial plaque picks. The resulting virus was uniformly lethal
to mice after intraperitoneal inoculation [14]. Pathologic
evaluation of infected mice identified similarities and dif-
ferences between this model [14,15] and infections in
nonhuman primates [16,17]. Similarities include the tro-
pism of the virus for monocytes/macrophages and high
viral titers in the spleen and liver tissues after infection
[reviewed in [18]]. The mean time to death of infected
mice is approximately 5–10 days, which is similar to that
observed in infected cynomolgus and rhesus macaques.
A viable lethal mouse model for Marburg virus is critical
to the filovirus vaccine research program to understand
the immune mechanisms that need to be induced, or
avoided, by vaccination. Furthermore, a mouse model
would speed the testing and evaluation of new Marburg
therapeutic candidates. This effort is currently impeded
due to limitations in the numbers of guinea pigs that can
be evaluated at one time (based on BSL-4 space limita-
tions, as well as physical demands on investigators and
technicians) and the large amounts of compounds that
must be synthesized or purified for testing in guinea pigs,
which are 20–50× the size of mice. The purpose of this
work was to select a marburgvirus that caused death
within a similar timeframe as monkeys or humans (7–10
days) in severe combined immunodeficiency (scid) mice.
To accomplish this goal, we repeatedly passaged the liver
homogenates of MARV-infected scid mice and then
recorded their time to death. Once we identified rapidly
lethal mouse-adapted viruses, we characterized the mod-
els by immunology and pathology studies. These scid
mouse-adapted viruses will be used to explore the viru-
lence factors associated with marburgvirus infection. Fur-
thermore, the scid models of MARV infection will be
particularly useful for screening candidate therapeutics for
their ability to directly diminish viral replication in the
absence of adaptive immune responses.
Methods
Virus and cells
Human-derived (wild-type) and mouse-adapted MARV-
Musoke, -Ravn, and -Ci67 virus stocks were propagated
no more than three passages in Vero or VeroE6 cells. The
human-derived (wild-type) and mouse-passaged MARV-
Musoke, -Ravn, and -Ci67 plaques were counted by stand-
ard plaque assay on Vero cells [19]. MARV-infected cells
and animals were handled under maximum containment
in a BSL-4 laboratory at the United States Army Medical
Research Institute of Infectious Diseases.
Animals
BALB/c severe combined immunodeficient (scid) mice,
aged 4 to 8 weeks, of both sexes, were obtained from
National Cancer Institute, Frederick Cancer Research and
Development Center (Frederick, MD). Mice were housed
in microisolator cages and provided autoclaved water and
chow ad libitum. Research was conducted in compliance
with the Animal Welfare Act and other federal statutes and
regulations relating to animals and experiments involving
animals and adhered to principles stated in the Guide for
the Care and Use of Laboratory Animals, National Research
Council, 1996. The facility where this research was con-
ducted is fully accredited by the Association for Assess-
ment and Accreditation of Laboratory Animal Care
International.
Mouse adaptation
The general approach to adapt MARV to mice was based
on virus passage in scid (BALB/c background) mice to
avoid usage of suckling mice to develop a lethal mouse-
adapted Marburg virus. The goal was to isolate the viral
population that was capable of migrating to target tissues/
organs (i.e., liver) at the earliest time point. Each group
consisted of 10 mice that were inoculated intraperito-
neally (IP) with 1000 pfu of Marburg virus (isolate
Musoke, Ci67, or Ravn). Two mice were euthanized on
day 7, the livers removed, pooled, and homogenized in 10
ml of PBS. The liver homogenates were blindly passed
(200  µl IP) and used to infect new mice to evaluate
lethality of the next virus passage. Lethality was moni-
tored in the remaining eight mice of each passage. The
supernatants of the liver homogenates from each passageVirology Journal 2007, 4:108 http://www.virologyj.com/content/4/1/108
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were introduced onto Vero cells to determine the viral tit-
ers by plaque assay [19].
Viral challenge with 'scid-adapted' MARV
For the characterization studies, scid mice were injected IP
with ~1000 pfu of 'scid mouse-adapted' MARV-Musoke,
passage (P)10; Ravn P(10); or Ci67, P(15) diluted in PBS.
After challenge, mice were observed at least twice daily for
illness and death and in some experiments, daily weights
were determined for each infected group.
Hematologic studies
For mice, blood samples were obtained under anesthesia
by cardiac puncture. Viremia was assayed by traditional
plaque assay [19]. Hematological, cytokine, and D-dimer
levels, as well as liver-associated enzymes, were measured
as previously described [20,21].
Pathologic sampling
Four animals from each group were randomly chosen for
euthanasia on 2, 4, 6, and 8 days postchallenge for gross
necropsy. A full complement of tissues from each mouse
was fixed in 10% neutral buffered formalin and held in
the BSL-4 laboratory for >21 days. The tissues were
embedded in paraffin, sectioned for histology, and
stained with hematoxylin and eosin for routine light
microscopy or were stained by an immunoperoxidase
method (Envision System – DAKO Corporation, Carpin-
teria, CA), using a mixture of two mouse monoclonal
antibodies against MARV nucleoprotein (NP) and glyco-
protein, or by the TUNEL method to detect apoptotic cells
within the tissue samples.
Adminstration of antisense PMO and filovirus-specific 
antisera
Two groups of 10 scid mice were each administered 1 ml
of convalescent sera from guinea pigs that had survived
either EBOV or MARV infection. The antibodies were
administered IP 1 h after challenge. Both pools of antisera
had 80% plaque reduction-neutralization titers of >1:160
against the homologous virus, but <1:20 against the het-
erologous virus. Alternately, another group of 10 scid
mice were administered IP with 1 mg of a mixture of four
MARV-specific phosphodiamidate morpholino oligomers
(PMOs) targeting the AUG start site of VP24, VP35, NP,
and L (kind gift of Dr. P.L. Iversen of AVI BioPharma, Inc.,
Corvallis, OR) 1 h after challenge. A control group
received saline (i.e., vehicle) alone. The mice were chal-
lenged with 1000 pfu of 'scid-adapted' MARV-Ci67 and
monitored for survival.
Results
Adaptation of Marburg viruses to scid mice
Previously, an Ebola Zaire mouse-adapted virus was
developed by performing 9 sequential passages of Ebola
Zaire '76 virus in suckling mice [14]. We chose to take a
slightly different approach, by repeatedly passaging
MARV-Ci67, -Musoke, or -Ravn in scid mice after initial
inoculation with the wild-type (i.e. human-derived)
viruses. The livers of two mice were harvested on day 7–8
after each infection, pooled together, homogenized, and
blind-passaged into naïve scid mice until a mean time-to-
death (MTD) of ≤10 days was observed through several
passages (Figure 1A–C). The starting time to death of the
scid mice varied after injection with the wild-type MARV
isolates. MARV-Musoke began with the highest MTD of
61.5 (± 9.67) days and dropped to 9.375 (± 1.30) days
within 10 passages. For MARV-Ci67, the MTD was 51.6 (±
4.98) days for the wild-type virus and was 7.75 (± 0.46)
days after 15 passages. The MTD for MARV-Ravn began at
39.4 (± 5.48) days and was 10.3 (± 0.71) days after 10 pas-
sages in scid mice. The viral titers in the liver homogenates
from each passage were determined using plaque assay
and we found an upward trend in the viral titers amongst
the liver homogenates with increasing passage in mice
(Figure 1D–F). The increase in viral titer in the day 7 liver
homogenates seemed to correspond with a decrease in the
MTD of the inoculated mice.
Characterization of the 'scid-adapted' MARV mouse 
models
We next intended to characterize the rapidly lethal 'scid-
adapted' mouse models of MARV-Musoke, -Ravn, and -
Ci67 via serial sampling studies of infected scid mice. It
was of particular interest to determine if the infection
caused similar laboratory, immunological, and patholog-
ical responses in mice, as was observed in MARV-infected
guinea pigs and nonhuman primates. Within 3–4 days
after injection with the 'scid-adapted' MARV strains, mice
developed anorexia, a hunched appearance, and exhibited
decreased grooming. Some mice also appeared to have
blood in their urine and many mice developed hind-limb
paralysis after 'scid-adapted' MARV infection (data not
shown).
As expected, there was a noticeable and steady weight loss
in mice infected with the 'scid-adapted' MARV beginning
around 4–5 days after infection (Figure 2A). Similar to
what is seen in guinea pigs and monkeys, infection with
the 'scid-adapted' MARV viruses caused detectable viremia
within 2 days of infection (Figure 2B). The viremia in all
the mice increased logarithmically over the course of the
infection and peaked around 106 pfu/ml in the serum at
days 6–8 (Figure 2B). Serum levels of blood urea nitrogen
(BUN) and glucose dropped sharply over time after infec-
tion of the scid mice (Figure 2C–D). As is seen in all other
models of filovirus infection, indicators of liver health
such as alanine transaminase (ALT) and aspartate
transaminase (AST) function increased as the MARV dis-
ease progressed (Figure 2E–F). As shown by the totalVirology Journal 2007, 4:108 http://www.virologyj.com/content/4/1/108
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number of circulating white blood cells (WBC), percent-
age of lymphocytes, and absolute numbers of lym-
phocytes within the blood of the 'scid-adapted' MARV-
infected mice, the very low number of circulating WBC
and lymphocytes remained fairly steady until very late in
the disease (Figure 3A–C). Most of the cells in the lym-
phoid system of scid mice are NK cells, except for a few
immature B or T cells due to 'leakiness' of the scid system,
Adaptation of MARV to severe combined immunodeficiency (scid) mice Figure 1
Adaptation of MARV to severe combined immunodeficiency (scid) mice. Groups of scid mice (n = 10) were infected 
with ~1000 pfu of wild-type MARV-Ci67, -Musoke, or -Ravn. The livers of two mice from each group were harvested 7–8 days 
after infection, pooled together, homogenized, and blind-passaged into a new group of naïve scid mice. Blind passaging pro-
ceeded until a mean time-to-death of 7–10 days was observed consistently through several passages. (A-C) The remaining 
eight mice from each group were monitored for survival and the data are presented as the time-to-death for each animal (filled 
circles) and the mean time-to-death (line). (D-F) The viral titers in the pooled liver homogenates were determined after each 
passage in scid mice. P15: Passage 15, P10: Passage 10.Virology Journal 2007, 4:108 http://www.virologyj.com/content/4/1/108
Page 5 of 13
(page number not for citation purposes)
and this explains the low WBC and lymphocyte counts in
Figure 3A–C. A steady decrease in the number of platelets
in the blood after infection was observed of the scid mice
with the 'scid-adapted' MARV (Figure 3D). As would be
expected with a coagulopathic disease and similar to filo-
virus infections in nonhuman primates [20,22], we
Weight loss, viremia and serum chemistry values of mice infected with 'scid-adapted' MARV Figure 2
Weight loss, viremia and serum chemistry values of mice infected with 'scid-adapted' MARV. Scid mice were 
infected with 1000 pfu of the indicated 'scid-adapted' MARV (Ci67 P15, Musoke P10 or Ravn P10). (A) The weight of groups of 
10 mice was assessed daily after infection with the 'scid-adapted' MARV. The data are expressed as the average weight of the 
mice in each group. (B) Viral titers were measured using standard plaque assay on serum samples obtained from terminal car-
diac punctures of infected mice on 0, 2, 4, 6 or 8 days postinfection. Levels of (C) Blood urea nitrogen (BUN), (D) glucose (E) 
alanine transaminase (ALT), and (F) aspartate transaminase (AST) were measured at the indicated timepoints using serum col-
lected by terminal cardiac puncture. Data for panels B-F are expressed as the average of values from four to five mice/time-
point and error bars indicate the standard deviation.Virology Journal 2007, 4:108 http://www.virologyj.com/content/4/1/108
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observed elevations in serum d-dimer levels by ELISA with
values >500 ng/ml by 6–8 days post infection (data not
shown).
Pathology characterization of the 'scid-adapted' MARV 
mouse models
Besides the noticeable and steady weight loss observed
beginning around 4–5 days after infection, the most obvi-
ous and consistent gross necropsy finding in mice infected
with the "scid-adapted" MARV occurred in the liver. When
compared to uninfected scid mice (Figure 4A), livers from
MARV-infected scid mice were diffusely enlarged with
rounded edges filling up to one-third of the abdominal
cavity and mildly displacing abdominal organs (Figure
4B). Furthermore, the livers had become diffusely yellow-
ish-tan with an accentuated reticulated pattern and were
extremely friable. Also consistently noted was that the
blood of the 'scid-adapted' MARV-infected mice failed to
clot post-mortem. To further characterize the lethal
mouse models of MARV-Musoke, -Ravn, and -Ci67, histo-
logical analysis was performed on tissues from scid mice
at 0, 2, 4, 6 and 8 days after infection. Histological lesions
were mainly limited to the lymphoid organs and the liver.
Compared to uninfected scid mice (Figure 5A–B), within
the livers of mice infected with "scid-adapted" MARV,
there was single-cell hepatocellular necrosis with neu-
trophilic infiltrates beginning at day 4 which progressed
from multifocal to coalescing areas of moderate to severe
hepatocellular degeneration and necrosis (Figures 5C and
5E) by days 6 and 8. Fatty cell degeneration of the remain-
ing hepatocytes was also a consistent finding at days 6 and
8. TUNEL-positive apoptotic-like bodies were frequently
co-located within areas of hepatocellular necrosis and foci
of neutrophilic inflammation (data not shown). Immu-
nohistochemically, within 4 days of infection, many
hepatocytes and Kupffer cells expressed strong surface
immunoreactivity for MARV antigen (Figure 5D) and
within 6 days, almost all hepatocytes and Kupffer cells
were positive for MARV antigen.
Hematologic changes in mice infected with 'scid-adapted' MARV Figure 3
Hematologic changes in mice infected with 'scid-adapted' MARV. Scid mice were infected with 1000 pfu of Ci67 P15, 
Musoke P10 or Ravn P10 'scid-adapted' MARV or left uninfected (naïve). Whole blood was collected from individual mice (n = 
4–5/timepoint) in EDTA via terminal cardiac puncture at the indicated timepoints. (A) Total numbers white blood cells 
(WBC), (B) percentage of lymphocytes, (C) absolute numbers of lymphocytes, and (D) platelet counts in the blood were 
assessed and are presented as the mean value (± standard deviation).Virology Journal 2007, 4:108 http://www.virologyj.com/content/4/1/108
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As compared to the spleens of uninfected mice (Figures
6A–B), there was multifocal lymphocyte depletion and
lymphocytolysis in the periarteriolar lymphoid sheaths
(PALS) and follicles of the MARV-infected scid mice (Fig-
ures 6C–F). These changes were minimal to mild at 4 days
postinfection, but more severe by day 6 postinfection.
Much of this lymphocyte damage appeared due to apop-
tosis of cells within the red and white pulp based on
TUNEL staining of tissues (Figure 7). We observed
increased numbers of apoptotic-like bodies labeled by
TUNEL as early as days 2 and 4 postinfection, with greater
numbers of TUNEL-positive bodies at days 6 and 8 postin-
fection. In mice killed at 6 or 8 days postinfection, the
spleens of infected mice contained large, lymphoblastic
cells within splenic marginal zones (Figure 6G). Consist-
ent with previous studies in other filovirus animal models
[14-16], the majority of the MARV-infected cells within
the spleen were located within the red pulp and appeared
to be phagocytic cells such as macrophages and dendritic
cells (Figure 6H).
Although no histologic changes were observed in the
mesenteric lymph nodes at day 2 as compared to lymph
nodes of uninfected mice (Figure 8A–B), cells labeled for
Marburg virus antigen were occasionally present in med-
ullary cords, surrounding high endothethelial vessels, and
in the subcapsular sinuses at this timepoint (data not
shown). Low to moderate numbers of virus-labeled histi-
ocytes were present in the subcapsular, cortical, and med-
ullary sinuses and parafollicular cells at days 4 and 6
postinfection. By day 4, there was minimal to mild lym-
phoid depletion and a slight increase in the number of
tingible body macrophages in the mesenteric lymph
nodes of all mice examined (Figure 8C). At days 6 and 8,
moderate lymphoid depletion and lymphocytolysis were
present in all mesenteric lymph nodes (Figure 8D–F).
Significant histologic or immunohistochemical findings
attributed to "scid-adapted" MARV were not noted in any
other tissues examined except the thymus and adrenal
glands. Rarely, few MARV infected medullary cells inter-
preted as either thymic macrophages or dendritic interdig-
itating cells were observed at day 4. Additionally, MARV
antigen was observed in few scattered cortical cells of the
zona fasciculata and zona reticularis at days 6 and 8.
Use of the 'scid-adapted' MARV model to assess the 
efficacy of potential therapeutics for MARV
To demonstrate the utility of our recently developed and
characterized 'scid-adapted' MARV (Ci67, Musoke, and
Ravn) in screening potential anti-MARV therapeutics, we
treated scid mice that were infected with 'scid-adapted'
MARV-Ci67. Since the scid mice do not have functional B
or T cells and cannot mount an adaptive response to clear
the virus, we only expected to see a delay in the mean
time-to-death and not a survival benefit in these experi-
ments. In the first portion of this experiment, 1 ml of
pooled sera from convalescent guinea pigs that were pre-
viously infected with EBOV-Zaire or MARV-Musoke was
administered IP 1 h after challenge to the MARV (Ci67)-
infected scid mice. The scid mice that were treated with
MARV convalescent sera had a MTD of >23 days (Figure
9). This was greatly increased when compared to the scid
mice that had been treated with sera from EBOV convales-
cent guinea pigs (MTD = 12 days, P value < 0.001). Addi-
tionally, 40% of scid mice receiving anti-MARV sera
survived until euthanasia at >70 days post infection with
scid-adapted MARV-Ci67. In the second portion of this
experiment, we tested the efficacy of a combination of
four anti-MARV PMOs targeting VP24, VP35, NP and L
(Figure 9). Scid mice that received the combination of
anti-MARV PMO molecules at 1 h postinfection with
'scid-adapted' MARV-Ci67 had a significant delay in their
mean time to death of 14 days, as compared to those
receiving only saline (MTD = 9 days, P value < 0.001).
Because transfer of antibody [23,24] or treatment with
Gross liver abnormalities upon necropsy of scid mice  infected with 'scid-adapted' MARV Figure 4
Gross liver abnormalities upon necropsy of scid mice 
infected with 'scid-adapted' MARV. (A) Livers of unin-
fected scid mice appear normal at the time of necropsy. (B) 
The livers from MARV-Ci67-infected scid mice were diffusely 
enlarged with rounded edges filling up to one-third of the 
abdominal cavity and mildly displacing abdominal organs. 
Additionally, the livers had become distinctively pale with an 
accentuated reticulated pattern.Virology Journal 2007, 4:108 http://www.virologyj.com/content/4/1/108
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anti-MARV PMOs [Warfield et al., unpublished data] can
protect guinea pigs, we feel that the delay to death
observed in this model is an important indicator of anti-
viral activity of these potential MARV treatments.
Discussion
In previous studies, scid mice became ill and died within
3–4 weeks after inoculation with ZEBOV ('76), Sudan
EBOV, or GP-adapted MARV-Ravn, but not with the other
viruses [25]. However, the scid mice in these studies were
only observed for 40 days after the infection – a much
shorter time than we found required to produce lethal dis-
ease with the human-derived, wild-type viruses. The MTD
of scid mice infected with the wild-type MARV isolates
was not previously reported elsewhere. We found the
time-to-death using wild-type MARV infections in scid
Histological changes in livers of mice infected with 'scid-adapted' MARV Figure 5
Histological changes in livers of mice infected with 'scid-adapted' MARV. Scid mice were challenged IP with 1000 pfu 
of 'scid-adapted' MARVCi67 and tissue samples were collected on days 0, 2, 4, 6, and 8 after challenge (n = 4–5/group). (A, C, 
and E) Tissues from the MARV-infected mice were stained with hematoxylin and eosin and representative pictures from day 0 
(A), 4 (C), and 6 (E) are shown. The liver from the MARV-infected mouse contains multifocal necrosis, hepatocellular disrup-
tion, fatty cell degeneration, scattered hepatocellular viral inclusions, and inflammation composed of variable numbers of neu-
trophils and lesser numbers of macrophages and lymphocytes. (B, D, and F) Immunohistochemistry was performed on tissue 
sections from days 0 (B), 4 (D), and 6 (F) and MARV antigen appears brown. In the liver, MARV antigen is localized at the 
hepatocellular surface and most prominently noted along the sinusoids. Magnifications for A-B and D-F were 20× and panel C 
is shown at 40×.Virology Journal 2007, 4:108 http://www.virologyj.com/content/4/1/108
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Histological changes in spleens of mice infected with 'scid-adapted' MARV Figure 6
Histological changes in spleens of mice infected with 'scid-adapted' MARV. Scid mice were challenged IP with 1000 
pfu of 'scid-adapted' MARV-Ci67 and tissue samples were collected on days 0, 2, 4, 6, and 8 after challenge (n = 4–5/group). 
(A-G) Tissues from the MARV-infected mice were stained with hematoxylin and eosin and representative pictures from day 0 
(A-B), 4 (C-D), and 6 (E-G) are shown. (A-B) Control scid mouse sampled at day 0 (i.e. uninfected) contain abnormal spleen 
morphology due to lack of B and T lymphocytes. (C-F) Spleens from the MARV-infected scid mice at days 4 and 6 display 
increasingly more visual loss of cells in both the red and white pulp. (G) At late stages of the disease, the spleen contains nota-
ble necrosis/apoptosis of lymphocytes often with tingible body macrophages and large lymphoblasts in the white pulp. (H) 
Immunoperoxidase stain of a spleen from a scid mouse at 6 days postinfection showing presence of Marburg viral antigen 
(brown). Magnifications were 4× for panels A, C, and E, 20× for panels B, D, and F, and 40× for panels G-H.Virology Journal 2007, 4:108 http://www.virologyj.com/content/4/1/108
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mice much too long (50–70 days) to feasibly screen the
efficacy of a large number of potential therapeutics in vivo.
Therefore, we passaged the viruses until the time to death
was consistently in the range of 7–10 days. These more
virulent 'scid-adapted' viruses will allow for more rapid
and efficient testing of candidate prophylactic and thera-
peutic treatments against multiple MARV isolates.
Initial serial sampling studies to characterize the pathol-
ogy of these more virulent, scid-adapted MARV strains
indicate similarities to the filovirus disease observed in
other models. After parenteral challenge, the incubation
period for MARV is 2 to 6 days, with death typically occur-
ring between 7 and 11 days after infection in both guinea
pigs and nonhuman primates [26-30]. Initial indicators of
MARV disease in all the animal models include fever, ano-
rexia, rash, huddling, weight loss, dehydration, and
diarrhea. More severe complications such as prostration,
failure to respond to stimulation, hind limb paralysis, and
bleeding from injection sites and/or body orifices develop
at later times after infection (i.e., 6–10 days) [26-30]. As
noted here and in other models, the liver and spleen are
tissues most consistently affected by MARV, as assessed by
gross appearance, microscopy and histology. Based on
pathology studies of the scid mice, guinea pigs, and non-
human primates, the primary targets of MARV infection
appear to be phagocytic cells, followed by hepatocytes,
endothelial cells and fibroblastic cells [26-30]. Clinically,
the scid mouse model appears to also be similar to the
guinea pig and nonhuman primate models. MARV virus
was present at increasingly high titers in the blood (Figure
2A), liver, spleen, kidneys, and other major organs (data
not shown). Furthermore, early hematological and immu-
nological changes included lymphopenia, variable neu-
trophilia, and profound thrombocytopenia [Figure 4 and
[26-30]]. Notable alterations in serum chemistry levels,
especially liver enzymes, occurred with increasing severity
after infection (Figure 3). However, unlike nonhuman pri-
mates, rodents such as mice, guinea pigs, and hamsters are
not susceptible to primary human isolates of MARV virus
directly from blood or organ homogenates derived from
infected patients [27,29-31].
Apoptosis within the spleen and liver of 'scid-adapted' MARV-infected mice Figure 7
Apoptosis within the spleen and liver of 'scid-adapted' MARV-infected mice. Sections of the spleen and liver from 
mice infected with 'scid-adapted' MARV-Ci67 were stained using a TUNEL assay. (A-B) Control scid mouse sampled at day 0 
(i.e. uninfected) contain TUNEL-positive cells, indicated by brown staining, in the spleen (A) and liver (B) due to natural turno-
ver of naïve 'break-through' lymphocytes. (C-D) Increased number of TUNEL-positive cells in the spleen (C) and liver (D) of 
MARV-infected scid mice at day 6 postinfection.Virology Journal 2007, 4:108 http://www.virologyj.com/content/4/1/108
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Progression of histologic lesions within the mesenteric lymph nodes of mice infected with "scid-adapted" MARV Figure 8
Progression of histologic lesions within the mesenteric lymph nodes of mice infected with "scid-adapted" 
MARV. Scid mice were challenged intraperitoneally with 1000 plaque-forming units of 'scid-adapted' MARV-Ci67 and tissue 
samples were collected on days 0, 2, 4, 6, and 8 after challenge (n = 4–5/group). (A-F) Tissues from the MARV-infected mice 
were stained with hematoxylin and eosin and representative pictures from day 0 (A), day 2 (B), day 4 (C), and days 6 and 8 
(D, E, F) are shown. (A) Control scid mouse sampled at day 0 (i.e. uninfected) contain abnormal lymph node morphology due 
to a paucity of B and T lymphocytes and failure of follicle development. (B) No significant histologic changes compared to unin-
fected lymph nodes observed at day 0. (C) By day 4, mesenteric lymph nodes from the MARV-infected scid mice exhibited 
minimal to mild lymphoid depletion and a slight increase in the number of tingible body macrophages. (D, E) At days 6 and 8, 
lymphoid depletion and lymphocytolysis was a consistent finding in the mesenteric lymph nodes of all MARV-infected scid mice. 
(F) At day 8, note the increased numbers of tingible body macrophages containing variably sized apoptotic-like bodies. Magnifi-
cations were 10× for panels A, B, C, D, and E and 40× for panel F. Tingible body macrophages are indicated by arrow heads.Virology Journal 2007, 4:108 http://www.virologyj.com/content/4/1/108
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Rodents infected with filoviruses appear to have slightly
different coagulopathic responses than filovirus-infected
nonhuman primates [14,26-30,32]. Similarities of the
models include profound and rapid loss of circulating
platelets, increased D-dimer levels, and uncontrolled
bleeding (Figure 3D, data not shown, and [32]). For
EBOV, rodents do not display all the characteristics of dis-
seminated intravascular coagulation (DIC) that filovirus-
infected nonhuman primates show including prolonga-
tion of PT and aPTT, circulating fibrin degredation prod-
ucts (FDPs), decreased plasma fibrinogen, and increased
tissue fibrin deposition [32]. Not all these parameters
have yet been tested for the MARV scid mouse model and
will surely be the subject of future work.
Sequence comparisons of the original wild-type and more
virulent scid-adapted MARV are required. Based on previ-
ous reports with mouse and guinea pig-adapted EBOV
[18,33,34], we predict changes in VP24, VP35, NP, and L
are likely to be important for enhanced virulence of the
'scid-adapted' MARV. VP24 was recently implicated in
host pathogenicity as VP24 is an interferon antagonist
that functions by binding karyopherin-α1 and blocking
nuclear accumulation of the interferon signaling molecule
stat1 [35,36]. The NP, VP35, and L proteins are all critical
for viral replication and alterations in these proteins may
lead to advantages in viral replication/growth within a
given host species. NP is the viral nucleoprotein that
tightly couples with the viral RNA [37]. Together, the L
protein, VP30, and VP35 form the filovirus RNA-depend-
ent RNA polymerase [37]. The VP35 is also implicated in
blocking interferon (IFN) type-I responses in filovirus-
infected cells by inhibiting double-stranded RNA-medi-
ated activation of interferon regulatory factor 3, a tran-
scription factor which triggers expression of interferon
and interferon-stimulated genes [38-41]. Future experi-
ments using reverse genetics could help demonstrate
which of the acquired mutations were important for adap-
tation to mice.
This scid mouse model of MARV infection has obvious
uses as a model for analysis of therapeutics and candidate
antibodies. It will be much more efficient for the purposes
of quickly screening lead compounds and neutralizing
antibodies than guinea pigs or nonhuman primates.
Before the development of this novel scid mouse model of
MARV, a large quantity of antiviral compound and/or
antibodies was required to achieve relevant physiological
levels in guinea pigs, which are 20–50 times larger than
mice, for the purposes of initial in vivo efficacy studies.
Furthermore, guinea pigs require much larger cages, limit-
ing the number of animals within a study and are also
much more difficult and dangerous to handle under BSL-
4 conditions than mice, requiring at least two laboratory
personnel for treatments and challenges. A delay in time
to death in this newly developed scid mouse model of
MARV infection will indicate a positive result that should
be followed up in the more intensive and expensive
guinea pig studies. Thus, this novel MARV mouse model
will allow for faster and more efficient in vivo screening of
potential MARV prophylactics and therapeutics.
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